Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
about
Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advancesThe metabolic and mitogenic properties of basal insulin analoguesMolecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analoguesInsulin and insulin like growth factor II endocytosis and signaling via insulin receptor BA framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues.In vitro metabolic and mitogenic signaling of insulin glargine and its metabolitesInsulin analogs and cancer: a note of caution.Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin.Logical analysis of timing-dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways.Genetic engineering in mice: impact on insulin signalling and action.Agonism and antagonism at the insulin receptor.Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics.Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts.Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinityMammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse modelLigand-Binding Affinity at the Insulin Receptor Isoform-A and Subsequent IR-A Tyrosine Phosphorylation Kinetics are Important Determinants of Mitogenic Biological Outcomes.Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cellsInsulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform AInsulin analogs and cancer.Insulin therapy and cancer in type 2 diabetes.Oxidative Stress Parameters and Erythrocyte Membrane Adenosine Triphosphatase Activities in Streptozotocin-induced Diabetic Rats Administered Aqueous Preparation of Kalanchoe Pinnata Leaves.New players for advanced prostate cancer and the rationalisation of insulin-sensitising medicationAchieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors.Vascular effects of rapid-acting insulin analogs in the diabetic patient: a reviewPrecursor IGF-II (proIGF-II) and mature IGF-II (mIGF-II) induce Bcl-2 And Bcl-X L expression through different signaling pathways in breast cancer cells.Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.Structural basis of the aberrant receptor binding properties of hagfish and lamprey insulins.Uptake and metabolic fate of [HisA8,HisB4,GluB10,HisB27]insulin in rat liver in vivo.IGF-I, IGF-II, and Insulin Stimulate Different Gene Expression Responses through Binding to the IGF-I Receptor.Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding.Insulin receptor membrane retention by a traceable chimeric mutant.Drosophila Insulin-Like Peptides DILP2 and DILP5 Differentially Stimulate Cell Signaling and Glycogen Phosphorylase to Regulate Longevity.
P2860
Q21131281-A1619AAC-FF1A-4B7F-A7B3-2068733782FEQ26991486-F65342B9-0031-49CD-9050-5A550F538F25Q28730070-892EE24E-62E3-4E05-B82F-AC965FB637BAQ28731843-2D00DF4B-5BEB-4736-ADEE-ABDC6B54CA13Q30538044-A3FF1BF3-0AD3-4A09-BC95-A259DD2F84ADQ30662831-77CAB17C-8F78-44F7-8B5D-8DBDEC7DC82DQ33537987-BBA09195-4808-4FAF-B641-055B66EE67F8Q33660524-060738C4-BC39-4BDE-BF46-A2522ED777B9Q33858986-11A9D618-1349-467F-9BBE-088B192F3F78Q33959945-0EDE8B0B-C1C4-42B9-B951-4125F2BAE1D3Q34438574-FAF595AA-E43B-4855-89AD-A65AAD7D8BA3Q34474052-2C3467EF-563F-48B7-8CE3-A9A38B0791B9Q34540334-7B57525A-FB28-47DB-9CFA-1EE645A899C1Q34620581-DE730983-FF37-49D0-8E56-A1080CB1015CQ35048673-EE96876E-1E3E-4444-933E-31D1713BFD91Q35095516-A80480A3-DAB8-4311-AEB3-8D0E98B51784Q35147769-68C3C98E-43ED-4E14-BA0A-35192B207741Q35824181-9E395E12-C78C-47C4-AF86-02A1B13C0CDBQ35863765-05E06D73-8097-45F1-887E-84141DDC8563Q35879542-27CD36AC-801B-4332-A4C8-6FD6541156C1Q35971416-AF689666-ABC3-4CD0-8C02-FB7382421CBDQ36417868-D585D357-D0F8-4A3E-8E86-A17169093E2AQ36657375-9196CB0B-859D-477B-A363-A9E5CE20374FQ36734036-2A8C3304-40EA-4F6D-92F2-636F28BBE94BQ36798972-764E5533-62B7-4EC3-A587-810B8A824CC6Q37167474-D3C50D90-2C6B-4FC6-A497-25A4461A80E0Q37414445-A3CE5093-5992-4725-9A7E-DBA659FA9DE0Q38255407-5BBD4AAE-AD24-4E1F-9E29-936D4B61A8B1Q41863848-442FBC28-A6B7-4261-88F6-5DDDDD541D4EQ42067510-70C2E782-1A2B-4AFD-BDDD-DD176262BB22Q42081392-4A9D3B4D-9E3E-4C4D-82DE-FADF95B0BEFAQ42993498-BDC812E5-801E-4CDB-AD0C-4534BE70D7D2Q43097788-018186DD-A93D-4238-9020-EADA014E66ECQ55035084-27FF922C-FA9A-48D7-AF96-A2AEA652A52A
P2860
Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Sustained signalling from the ...... ng increased mitogenic potency
@en
Sustained signalling from the ...... ng increased mitogenic potency
@nl
type
label
Sustained signalling from the ...... ng increased mitogenic potency
@en
Sustained signalling from the ...... ng increased mitogenic potency
@nl
prefLabel
Sustained signalling from the ...... ng increased mitogenic potency
@en
Sustained signalling from the ...... ng increased mitogenic potency
@nl
P2093
P2860
P356
P1433
P1476
Sustained signalling from the ...... ng increased mitogenic potency
@en
P2093
A G Lundemose
A R Sørensen
B F Hansen
F C Wiberg
G M Danielsen
P2860
P304
P356
10.1042/BJ3150271
P407
P478
315 ( Pt 1)
P577
1996-04-01T00:00:00Z